CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies
F-star, a biopharmaceutical company developing novel bispecific antibodies
with a focus on immuno-oncology, today announced the appointment of Dr Neil Brewis as Chief Scientific Officer.
These assets comprises FS102 and other Fcabs or bispecific antibodies
(mAb2 ) against oncology and immuno-oncology targets, generated through the company s Modular Antibody Technology platform.
This conference will present data and case studies on key topics such as antibody drug conjugates, bispecific antibodies
and overcoming the blood-brain barrier.
But at the same time that monoclonal antibodies have hogged the spotlight, their distant cousins, bispecific antibodies
, have been floating around.
Their topics include the humanization of antibodies, affinity maturation approaches for antibody lead optimization, antibody expression from bacteria to transgenic animals, the design and application of immunoconjugates for cancer therapy, and dual-targeting bispecific antibodies
as new therapeutic modalities for cancer.
DVD-Ig, which stands for dual-variable-domain immunoglobulin, is also known as bispecific antibodies
Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies
against cell surface molecules other than Fc-gamma receptor.
Morris Plains, NJ) announced the issuance of a new United States Patent 6,399,068, which covers therapeutic bispecific antibodies
for the treatment of cancers, especially B-cell malignancies, such as non-Hodgkin's lymphoma.
Adimab also announced the expansion of its existing research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies
targeting molecular targets identified by Lilly.
The preclinical data support further development of Xencor's CD38xCD3 bispecific antibodies
in multiple myeloma and other CD38+ malignancies.
Merck Serono, the biopharmaceutical division of Merck, and Sutro Biopharma, San Francisco, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies
, today announced a collaboration and license agreement to develop antibody drug conjugates (ADCs).